CA2686439A1 - Composant et dispositif de traitement des deficiences osseuses et cartilagineuses - Google Patents

Composant et dispositif de traitement des deficiences osseuses et cartilagineuses Download PDF

Info

Publication number: CA2686439A1
Authority: CA; Canada
Prior art keywords: collagen; growth factor; bmp; composition according; osteo
Prior art date: 2007-09-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002686439A

Other languages

English (en)

Inventor

Arne Briest

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SBF Synthetic Bone Factory GmbH

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-10

Filing date

2008-09-05

Publication date

2009-03-19

2008-02-29 Priority claimed from PCT/EP2008/001604 external-priority patent/WO2008107122A2/fr

2008-09-05 Application filed by Individual filed Critical Individual

2009-03-19 Publication of CA2686439A1 publication Critical patent/CA2686439A1/fr

Status Abandoned legal-status Critical Current

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 86
230000007547 defect Effects 0.000 title claims abstract description 39
210000000845 cartilage Anatomy 0.000 title claims abstract description 38
150000001875 compounds Chemical class 0.000 title description 3
239000000203 mixture Substances 0.000 claims abstract description 163
102000008186 Collagen Human genes 0.000 claims abstract description 160
108010035532 Collagen Proteins 0.000 claims abstract description 160
229920001436 collagen Polymers 0.000 claims abstract description 159
239000003102 growth factor Substances 0.000 claims abstract description 106
239000000463 material Substances 0.000 claims abstract description 95
238000000034 method Methods 0.000 claims abstract description 71
230000004069 differentiation Effects 0.000 claims abstract description 60
230000002138 osteoinductive effect Effects 0.000 claims abstract description 37
230000000694 effects Effects 0.000 claims abstract description 35
238000011049 filling Methods 0.000 claims abstract description 34
241001465754 Metazoa Species 0.000 claims abstract description 16
239000000126 substance Substances 0.000 claims abstract description 15
238000004519 manufacturing process Methods 0.000 claims abstract description 14
241000282414 Homo sapiens Species 0.000 claims description 65
102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 63
108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 63
229940112869 bone morphogenetic protein Drugs 0.000 claims description 63
102000004169 proteins and genes Human genes 0.000 claims description 37
108090000623 proteins and genes Proteins 0.000 claims description 37
238000002156 mixing Methods 0.000 claims description 34
239000013543 active substance Substances 0.000 claims description 29
230000000278 osteoconductive effect Effects 0.000 claims description 24
125000003275 alpha amino acid group Chemical group 0.000 claims description 22
239000011148 porous material Substances 0.000 claims description 22
102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 21
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 20
239000001506 calcium phosphate Substances 0.000 claims description 20
229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 20
229940078499 tricalcium phosphate Drugs 0.000 claims description 20
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 18
235000019731 tricalcium phosphate Nutrition 0.000 claims description 18
102000012422 Collagen Type I Human genes 0.000 claims description 17
108010022452 Collagen Type I Proteins 0.000 claims description 17
108010009583 Transforming Growth Factors Proteins 0.000 claims description 17
102000009618 Transforming Growth Factors Human genes 0.000 claims description 17
229910052751 metal Inorganic materials 0.000 claims description 15
239000002184 metal Substances 0.000 claims description 15
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 14
102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 14
229910010293 ceramic material Inorganic materials 0.000 claims description 14
239000007943 implant Substances 0.000 claims description 14
150000002739 metals Chemical class 0.000 claims description 14
229920000642 polymer Polymers 0.000 claims description 14
241000283690 Bos taurus Species 0.000 claims description 13
239000000654 additive Substances 0.000 claims description 13
239000000284 extract Substances 0.000 claims description 13
238000001356 surgical procedure Methods 0.000 claims description 13
241000283073 Equus caballus Species 0.000 claims description 12
230000034127 bone morphogenesis Effects 0.000 claims description 12
230000000996 additive effect Effects 0.000 claims description 11
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 10
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
239000003153 chemical reaction reagent Substances 0.000 claims description 10
239000000243 solution Substances 0.000 claims description 10
241000894006 Bacteria Species 0.000 claims description 9
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
239000000919 ceramic Substances 0.000 claims description 8
230000011164 ossification Effects 0.000 claims description 8
241000588724 Escherichia coli Species 0.000 claims description 7
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 7
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 7
230000003115 biocidal effect Effects 0.000 claims description 7
230000022159 cartilage development Effects 0.000 claims description 7
239000000824 cytostatic agent Substances 0.000 claims description 7
238000002513 implantation Methods 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
102000004127 Cytokines Human genes 0.000 claims description 6
108090000695 Cytokines Proteins 0.000 claims description 6
229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
230000035800 maturation Effects 0.000 claims description 6
239000011707 mineral Substances 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 6
102000009123 Fibrin Human genes 0.000 claims description 5
108010073385 Fibrin Proteins 0.000 claims description 5
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
241000238631 Hexapoda Species 0.000 claims description 5
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
108091005804 Peptidases Proteins 0.000 claims description 5
239000011248 coating agent Substances 0.000 claims description 5
238000000576 coating method Methods 0.000 claims description 5
229950003499 fibrin Drugs 0.000 claims description 5
101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 4
101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 4
102000035195 Peptidases Human genes 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 4
102000013275 Somatomedins Human genes 0.000 claims description 4
102000004142 Trypsin Human genes 0.000 claims description 4
108090000631 Trypsin Proteins 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
230000027455 binding Effects 0.000 claims description 4
230000001085 cytostatic effect Effects 0.000 claims description 4
230000013595 glycosylation Effects 0.000 claims description 4
102000045896 human BMP2 Human genes 0.000 claims description 4
230000000813 microbial effect Effects 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
230000002829 reductive effect Effects 0.000 claims description 4
230000000979 retarding effect Effects 0.000 claims description 4
239000008174 sterile solution Substances 0.000 claims description 4
239000012588 trypsin Substances 0.000 claims description 4
102000004506 Blood Proteins Human genes 0.000 claims description 3
108010017384 Blood Proteins Proteins 0.000 claims description 3
102000002068 Glycopeptides Human genes 0.000 claims description 3
108010015899 Glycopeptides Proteins 0.000 claims description 3
102000003886 Glycoproteins Human genes 0.000 claims description 3
108090000288 Glycoproteins Proteins 0.000 claims description 3
230000004071 biological effect Effects 0.000 claims description 3
238000004132 cross linking Methods 0.000 claims description 3
239000003431 cross linking reagent Substances 0.000 claims description 3
235000019833 protease Nutrition 0.000 claims description 3
230000001954 sterilising effect Effects 0.000 claims description 3
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 2
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 2
244000063299 Bacillus subtilis Species 0.000 claims description 2
235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
102000001187 Collagen Type III Human genes 0.000 claims description 2
108010069502 Collagen Type III Proteins 0.000 claims description 2
108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims description 2
102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
239000004365 Protease Substances 0.000 claims description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical class [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
230000002051 biphasic effect Effects 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
239000012948 isocyanate Substances 0.000 claims description 2
235000019419 proteases Nutrition 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
229940014800 succinic anhydride Drugs 0.000 claims description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
241000187747 Streptomyces Species 0.000 claims 1
230000004936 stimulating effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 15
239000000047 product Substances 0.000 description 15
239000011159 matrix material Substances 0.000 description 11
108010030102 COLLOSS E Proteins 0.000 description 9
230000008569 process Effects 0.000 description 9
230000008929 regeneration Effects 0.000 description 9
238000011069 regeneration method Methods 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
229940096422 collagen type i Drugs 0.000 description 7
239000000945 filler Substances 0.000 description 7
102000007000 Tenascin Human genes 0.000 description 6
108010008125 Tenascin Proteins 0.000 description 6
239000000725 suspension Substances 0.000 description 6
102000005593 Endopeptidases Human genes 0.000 description 5
108010059378 Endopeptidases Proteins 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000008439 repair process Effects 0.000 description 5
102000006395 Globulins Human genes 0.000 description 4
108010044091 Globulins Proteins 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
102000007327 Protamines Human genes 0.000 description 4
108010007568 Protamines Proteins 0.000 description 4
238000007792 addition Methods 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
229940048914 protamine Drugs 0.000 description 4
210000002435 tendon Anatomy 0.000 description 4
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
102000016359 Fibronectins Human genes 0.000 description 3
108010067306 Fibronectins Proteins 0.000 description 3
102000007547 Laminin Human genes 0.000 description 3
108010085895 Laminin Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
210000002805 bone matrix Anatomy 0.000 description 3
239000000316 bone substitute Substances 0.000 description 3
229940126864 fibroblast growth factor Drugs 0.000 description 3
229910052588 hydroxylapatite Inorganic materials 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000002188 osteogenic effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
229920000747 poly(lactic acid) Polymers 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
101150061927 BMP2 gene Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
101000958041 Homo sapiens Musculin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000723873 Tobacco mosaic virus Species 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000012620 biological material Substances 0.000 description 2
230000008468 bone growth Effects 0.000 description 2
230000010478 bone regeneration Effects 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
230000003399 chemotactic effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
102000046949 human MSC Human genes 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
229920002994 synthetic fiber Polymers 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
239000010936 titanium Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
101000984012 Gallus gallus Cadherin-1 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
102000009890 Osteonectin Human genes 0.000 description 1
108010077077 Osteonectin Proteins 0.000 description 1
102000004264 Osteopontin Human genes 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
-1 TGF-(31 Proteins 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241001447056 Uristes Species 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940050528 albumin Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000002977 biomimetic material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000004068 calcium phosphate ceramic Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000003321 cartilage cell Anatomy 0.000 description 1
230000003848 cartilage regeneration Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000002820 chemotaxin Substances 0.000 description 1
230000002648 chondrogenic effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000005238 degreasing Methods 0.000 description 1
230000002328 demineralizing effect Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
235000003869 genetically modified organism Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000002901 mesenchymal stem cell Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229920001230 polyarylate Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000005245 sintering Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000005641 tunneling Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
239000013598 vector Substances 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1
230000002034 xenobiotic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Oral & Maxillofacial Surgery (AREA)
Organic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

CA002686439A 2007-09-10 2008-09-05 Composant et dispositif de traitement des deficiences osseuses et cartilagineuses Abandoned CA2686439A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US99314607P	2007-09-10	2007-09-10
US60/993,146		2007-09-10
EPPCT/EP08/001604		2008-02-29
PCT/EP2008/001604 WO2008107122A2 (fr)	2007-03-08	2008-02-29	Composition pour traiter des défauts osseux et/ou cartilagineux
PCT/IB2008/002367 WO2009034452A2 (fr)	2007-09-10	2008-09-05	Composant et dispositif de traitement des déficiences osseuses et cartilagineuses

Publications (1)

Publication Number	Publication Date
CA2686439A1 true CA2686439A1 (fr)	2009-03-19

Family

ID=40452623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002686439A Abandoned CA2686439A1 (fr)	2007-09-10	2008-09-05	Composant et dispositif de traitement des deficiences osseuses et cartilagineuses

Country Status (7)

Country	Link
JP (1)	JP2010538691A (fr)
KR (1)	KR20100052430A (fr)
CN (1)	CN101631562A (fr)
AU (1)	AU2008299484A1 (fr)
CA (1)	CA2686439A1 (fr)
IL (1)	IL200820A0 (fr)
WO (1)	WO2009034452A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101400667B1 (ko) *	2011-04-22	2014-05-30	주식회사 나이벡	펩타이드에 의한 표면활성형 콜라겐 차폐막
JP2014156410A (ja) *	2013-02-14	2014-08-28	Nagoya Univ	組織形成用組成物及びその利用
GB201402648D0 (en) *	2014-02-14	2014-04-02	Athlone Inst Of Technology	Composition
CN105012995B (zh) *	2015-06-04	2018-03-09	武汉维斯第医用科技股份有限公司	一种含促骨愈合药物的胶原蛋白海绵及其制备方法
KR101694392B1 (ko) *	2016-06-02	2017-01-10	단국대학교 천안캠퍼스 산학협력단	통증 제어를 위한 전류 제어 기반 전기기계적 연골 성형 장치
BR112021006752A2 (pt) *	2018-10-12	2021-07-13	Theradaptive, Inc.	polipeptídeos incluindo uma sequência de ligação de betafosfato tricálcico e usos dos mesmos
CN109289088B (zh) *	2018-10-26	2021-04-27	福州大学	一种负载鸡血藤的ⅰ型/ⅲ型胶原复合支架
EP3695856A1 (fr) *	2019-02-13	2020-08-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Biomatériaux comprenant un échafaudage contenant un composé de minéraux et leurs utilisations en tant que substituts osseux
GB201917246D0 (en) *	2019-11-27	2020-01-08	Royal College Surgeons Ireland	A collagen scaffold

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5290763A (en) *	1991-04-22	1994-03-01	Intermedics Orthopedics/Denver, Inc.	Osteoinductive protein mixtures and purification processes
US20020114795A1 (en) *	2000-12-22	2002-08-22	Thorne Kevin J.	Composition and process for bone growth and repair
US7375077B2 (en) *	2003-09-19	2008-05-20	The Board Of Trustees Of The University Of Illinois	In vivo synthesis of connective tissues
DE102004036881A1 (de) *	2004-07-22	2006-02-16	Ossacur Ag	Bioresorbierbares Material zur Füllung von Knochendefekten

2008
- 2008-09-05 KR KR1020097021182A patent/KR20100052430A/ko not_active Withdrawn
- 2008-09-05 WO PCT/IB2008/002367 patent/WO2009034452A2/fr not_active Ceased
- 2008-09-05 CA CA002686439A patent/CA2686439A1/fr not_active Abandoned
- 2008-09-05 AU AU2008299484A patent/AU2008299484A1/en not_active Abandoned
- 2008-09-05 JP JP2010523606A patent/JP2010538691A/ja active Pending
- 2008-09-05 CN CN200880007545A patent/CN101631562A/zh active Pending
2009
- 2009-09-08 IL IL200820A patent/IL200820A0/en unknown

Also Published As

Publication number	Publication date
IL200820A0 (en)	2010-05-17
AU2008299484A1 (en)	2009-03-19
WO2009034452A2 (fr)	2009-03-19
JP2010538691A (ja)	2010-12-16
AU2008299484A2 (en)	2009-10-08
WO2009034452A4 (fr)	2009-08-20
WO2009034452A3 (fr)	2009-06-04
CN101631562A (zh)	2010-01-20
KR20100052430A (ko)	2010-05-19

Publication	Publication Date	Title
US8586070B2 (en)	2013-11-19	Composition and device for treating bone and/or cartilage defects
CA2686439A1 (fr)	2009-03-19	Composant et dispositif de traitement des deficiences osseuses et cartilagineuses
Bostrom et al.	1996	Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model
Damien et al.	1991	Bone graft and bone graft substitutes: a review of current technology and applications
Kroese-Deutman et al.	2005	Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants inserted at an ectopic site in rabbits
Dai et al.	2005	Repairing of goat tibial bone defects with BMP-2 gene–modified tissue-engineered bone
Geiger et al.	2003	Collagen sponges for bone regeneration with rhBMP-2
Boden et al.	1995	The Use of an Osteoinductive Growth Factor for Lumbar Spinal Fusion: Part II: Study of Dose, Carrier, and Species
Gothard et al.	2014	Tissue engineered bone using select growth factors: A comprehensive review of animal studies and clinical translation studies in man.
Caballé‐Serrano et al.	2017	Collagen barrier membranes adsorb growth factors liberated from autogenous bone chips
Duarte et al.	2017	Biomaterials and bioactive agents in spinal fusion
Hotz et al.	1994	Bone substitute with osteoinductive biomaterials—current and future clinical applications
Kasten et al.	2012	Comparison of platelet-rich plasma and VEGF-transfected mesenchymal stem cells on vascularization and bone formation in a critical-size bone defect
Schützenberger et al.	2012	The optimal carrier for BMP-2: a comparison of collagen versus fibrin matrix
US8524253B2 (en)	2013-09-03	Bone regeneration device
US20050136042A1 (en)	2005-06-23	Methods and compositions for tissue repair
Jabbari	2013	Osteogenic peptides in bone regeneration
JP2010512974A (ja)	2010-04-30	流動性のキャリア組成物およびその使用方法
KR102751476B1 (ko)	2025-01-08	자가 골 이식편 대체재
Wei et al.	2018	Augmentation of fracture healing by hydroxyapatite/collagen paste and bone morphogenetic protein‐2 evaluated using a rat femur osteotomy model
Oppenheimer et al.	2012	Current and emerging basic science concepts in bone biology: implications in craniofacial surgery
EP1539812B1 (fr)	2010-06-02	Biomateriaux osteo-inducteurs
Iwai et al.	2018	Bone regeneration by freeze‐dried composite of octacalcium phosphate collagen and teriparatide
Weng et al.	2021	Delivery of dimethyloxalylglycine in calcined bone calcium scaffold to improve osteogenic differentiation and bone repair
EP2185186A2 (fr)	2010-05-19	Composant et dispositif de traitement des déficiences osseuses et cartilagineuses

Legal Events

Date	Code	Title	Description
2014-11-06	FZDE	Discontinued	Effective date: 20140905